3 unknown, 1 recruiting. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 3, Recruiting 1 |
| Phase 2 | 3 | Unknown 3 |
Follow EBV-Positive DLBCL, Nos: new trials by email Literature Review of EBV-Positive DLBCL, Nos trials Research Report on EBV-Positive DLBCL, Nos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
Pyloric Stenosis, Hypertrophic (4) · Lymphoma, Large B-Cell, Diffuse (2) · Recurrence (2) · Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, Primary Effusion (1) · Plasmablastic Lymphoma (1) · Waldenstrom Macroglobulinemia (1)
Digestive System Diseases (4) · Gastric Outlet Obstruction (4) · Gastrointestinal Diseases (4) · Pyloric Stenosis (4) · Stomach Diseases (4) · Disease Attributes (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3)
Lenalidomide (1) · R-CHOP protocol (1) · Rituximab (1) · apatinib (1) · camrelizumab (1) · spartalizumab (1) · tislelizumab (1) · toripalimab (1)
Huiqiang Huang (3) · Schrödinger, Inc. (1)
China (3) · France (1) · Italy (1) · Moldova (1) · Poland (1) · Romania (1) · Spain (1) · Ukraine (1) · United States (1)